-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: TPP
Bi-partisan Senate Letter asking for 12 years of Data Protection in TPP
Senators Hatch and Kerry, along with 35 other Senators, sent a letter to Ambassador Kirk asking for 12 years of regulatory data protection consistent with U.S. law in the Trans Pacific Partnership Agreement. We are united in urging you to propose a strong minimum term of regulatory data protection for biologics consistent with U.S. law. As you are aware, U.S. law provides for a 12-year term of regulatory data protection for biologics and we believe that should serve Read More >
Data Protection, Trans Pacific Partnership, and the US-Jordan FTA (Post 2 of 2)
This post is a continuation of a previous post: Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2). 4. Oxfam criticizes pharmaceutical innovators for not making all of their innovative drugs available in Jordan. Ryan responds: a. Innovator companies introduced few new drugs before IP reform because local companies were using their know-how and clinical data to get marketing approval and brochures describing the drug’s therapeutic function and side effects Read More >
Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2)
The Trans Pacific Partnership (TPP) negotiation does not yet include a section on data protection (typically included in the Pharmaceutical Chapter of Free Trade Agreements). Organizations against the inclusion of data protection in the TPP cite as evidence an Oxfam International study titled “All Costs, No Benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines.” The Oxfam paper concludes that “medicine prices have increased drastically, and TRIPS-plus rules were partly Read More >
